Browsing category:


Gemifloxacin Mesylate is a reliable and effectual antibiotic. Known as Factive, which is marketed by LG Life Sciences, the patent for gemifloxacin mesylate is due to expire on June 15, 2015. This once daily, 320 milligram tablet is the only FDA approved drug indicated for the treatment of acute bacterial exacerbation of chronic bronchitis caused[…]

Read More

Ertapenem Sodium, CAS# 153773-82-1 is a carbapenem-type antibiotic. Also known as the brand name Invanz, which is marketed by Merck, the patent for Invanz is expiring on November 21, 2015, opening the market for generic pharmaceutical options of this powerful antibiotic. Ertapenem sodium is unique in that it is extremely efficacious for treating a variety[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service